Literature DB >> 22475882

Rituximab for tumefactive inflammatory demyelination: a case report.

Xuewen Fan1, Ali Mahta, Philip L De Jager, Santosh Kesari.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22475882     DOI: 10.1016/j.clineuro.2012.03.010

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


× No keyword cloud information.
  5 in total

1.  Therapeutic management of severe relapses in multiple sclerosis.

Authors:  Carolyn Bevan; Jeffrey M Gelfand
Journal:  Curr Treat Options Neurol       Date:  2015-04       Impact factor: 3.598

Review 2.  Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders.

Authors:  Meredith C Frederick; Michelle H Cameron
Journal:  Curr Neurol Neurosci Rep       Date:  2016-03       Impact factor: 5.081

3.  Recurrent Fulminant Tumefactive Demyelination With Marburg-Like Features and Atypical Presentation: Therapeutic Dilemmas and Review of Literature.

Authors:  Aigli G Vakrakou; Dimitrios Tzanetakos; Theodore Argyrakos; Georgios Koutsis; Maria-Eleptheria Evangelopoulos; Elisabeth Andreadou; Maria Anagnostouli; Marianthi Breza; John S Tzartos; Elias Gialafos; Antonios N Dimitrakopoulos; Georgios Velonakis; Panagiotis Toulas; Leonidas Stefanis; Constantinos Kilidireas
Journal:  Front Neurol       Date:  2020-06-30       Impact factor: 4.003

4.  Treatment with Rituximab in the Acute Phase of Relapsing Remitting Multiple Sclerosis.

Authors:  Ayano Shima; Tsuyoshi Hamaguchi; Yasutake Tada; Masahito Yamada
Journal:  Intern Med       Date:  2019-08-28       Impact factor: 1.271

5.  A rare presentation of atypical demyelination: tumefactive multiple sclerosis causing Gerstmann's syndrome.

Authors:  Sharmilee Gnanapavan; Zane Jaunmuktane; Kelly Pegoretti Baruteau; Sakthivel Gnanasambandam; Klaus Schmierer
Journal:  BMC Neurol       Date:  2014-04-02       Impact factor: 2.474

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.